Under the terms of the research collaboration agreement, Spark will gain access to NeuExcell's neuroregenerative gene therapy platform and will collaborate with NeuExcell's research team. In addition, NeuExcell is eligible to receive upfront, license fee, R&D, and sales milestone payments up to approximately $190 million plus product royalties. Spark has the option to license the exclusive worldwide rights to NeuExcell's Huntington's disease program.

NeuExcell is developing adeno-associated virus-based neuroregenerative gene therapy to regenerate functional new neurons at the site of the neurodegeneration, according to the companies.

NeuExcell raises more than $10M
NeuExcell Therapeutics has raised more than $10 million in a series pre-A funding round led by Co-Win Ventures.

Senti Bio, Spark Therapeutics to develop next-gen gene therapies
Senti Biosciences (Senti Bio) and Spark Therapeutics are collaborating to develop next-generation precision gene therapies directed toward specific cell...

Dyno Therapeutics licenses AAV platform to Roche
Dyno Therapeutics has licensed its CapsidMap platform for the development of next-generation adeno-associated virus (AAV) vectors for gene therapies for...